1. Eslam, M, Sarin, SK, Wong, VW, et al The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020; 14: 889–919.
Google Scholar | Crossref | Medline2. Sarin, SK, Kumar, M, Eslam, M, et al Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2020; 5: 167–228.
Google Scholar | Crossref | Medline3. Younossi, Z, Anstee, QM, Marietti, M, et al Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11–20.
Google Scholar | Crossref | Medline4. Eslam, M, George, J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol 2020; 17: 40–52.
Google Scholar | Crossref | Medline5. Vilar-Gomez, E, Calzadilla-Bertot, L, Wai-Sun Wong, V, et al Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018; 155: 443–457.e17.
Google Scholar | Crossref | Medline6. Mittal, S, El-Serag, HB, Sada, YH, et al Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016; 14: 124–131.e1.
Google Scholar | Crossref7. Esmat, G, El-Sayed, MH, Hassany, M, et al One step closer to elimination of hepatitis C in Egypt. Lancet Gastroenterol Hepatol 2018; 3: 665.
Google Scholar | Crossref | Medline8. Alboraie, M, Youssef, N, Sherief, AF, et al Egyptian liver library: an indexed database for liver disease evidence in Egypt. Arab J Gastroenterol 2019; 20: 109–113.
Google Scholar | Crossref | Medline9. Shiha, G, Alswat, K, Al Khatry, M, et al Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and North Africa. Lancet Gastroenterol Hepatol 2020; 6: 57–64.
Google Scholar | Crossref | Medline10. Esslam, M, Fouad, Y, Attia, D, et al Increase metabolic dysfunction fatty liver disease related hepatocellular carcinoma in Egypt over a decade of period. Accepted abstract at Digital NAFLD Summit 2021 Abstract Book. Po 251, 2021.
Google Scholar11. Alem, SA, Gaber, Y, Abdalla, M, et al Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback. J Hepatol 2021; 74: 1261–1262.
Google Scholar | Crossref | Medline12. Fouad, Y, Gomaa, A, Semida, N, et al Change from NAFLD to MAFLD increases the awareness of fatty liver disease of primary care physicians and specialists. J Hepatol 2021; 74: 1254–1256.
Google Scholar | Crossref | Medline13. Eslam, M, Sanyal, AJ, George, J, et al MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999–2014.e1.
Google Scholar | Crossref | Medline14. Eslam, M, Newsome, PN, Sarin, SK, et al A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73: 202–209.
Google Scholar | Crossref | Medline15. Spearman, CW, Desalegn, H, Ocama, P, et al The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD. J Hepatol 2021; 74: 1256–1258.
Google Scholar | Crossref | Medline16. Clayton, M, Fabrellas, N, Luo, J, et al From NAFLD to MAFLD: nurse and allied health perspective. Liver Int 2021; 41: 683–691.
Google Scholar | Crossref | Medline17. Fouad, Y, Saad, ZM, Moeness, HM, et al Clinical validity of the diagnostic criteria for metabolic-associated fatty liver disease: a real-world experience. medRxiv 2020.
Google Scholar18. Shiha, G, Korenjak, M, Eskridge, W, et al Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 2021; 6: 73–79.
Google Scholar | Crossref | Medline19. Mendez-Sanchez, N, Arrese, M, Gadano, A, et al The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 2021; 6: 65–72.
Google Scholar | Crossref | Medline20. Gómez, MR, Ampuero, J. Looking for a new name for Non-alcoholic fatty liver disease in Spanish: Esteatosis Hepática Metabólica (EHmet). Rev Esp Enferm Dig 2021; 113: 161–163.
Google Scholar | Medline21. Tan, SS, Lee, YY, Ali, RAR, et al Endorsing the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 2021; 6: 163.
Google Scholar | Crossref | Medline22. Fouad, Y, Elwakil, R, Elsahhar, M, et al The NAFLD-MAFLD debate: Eminence vs evidence. Liver Int 2021; 41: 255–260.
Google Scholar | Crossref | Medline23. Fouad, Y, Waked, I, Bollipo, S, et al What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int 2020; 40: 1254–1261.
Google Scholar | Crossref | Medline24. Bayoumi, A, Gronbaek, H, George, J, et al The epigenetic drug discovery landscape for metabolic-associated fatty liver disease. Trends Genet 2020; 36: 429–441.
Google Scholar | Crossref | Medline